Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject ...
Stocktwits on MSN

ASBP stock soars 32% after favorable feedback from FDA for its aspirin – retail expects licensing negotiations soon

Aspire does not expect to conduct additional studies beyond its currently planned multicenter crossover clinical trial. ・The ...
Investing.com South Africa

Aspire Biopharma stock soars after FDA meeting clears path for heart attack drug

Investing.com -- Aspire Biopharma Holdings Inc (NASDAQ:ASBP) stock surged 60.6% in premarket trading Wednesday after the ...
The Desert Sun

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial ...

ESTERO, FLORIDA / ACCESS Newswire / September 3, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) (“Aspire” or the “Company”), developer of a multi-faceted patent-pending drug delivery technology, ...